Circulating Biomarkers to Identify Responders in Cardiac Cell therapy

Jesse V. Jokerst; Nicholas Cauwenberghs; Tatiana Kuznetsova; Francois Haddad; Timothy Sweeney; Jiayi Hou; Yael Rosenberg-Hasson; Eric Zhao; Robert Schutt; Roberto Bolli; Jay H. Traverse; Carl J. Pepine; Timothy D. Henry; Ivonne H. Schulman; Lem Moyé; Doris A. Taylor; Phillip C. Yang

doi:10.1038/s41598-017-04801-7

Circulating Biomarkers to Identify Responders in Cardiac Cell therapy

Jesse V. Jokerst, Nicholas Cauwenberghs, Tatiana Kuznetsova, Francois Haddad, Timothy Sweeney, Jiayi Hou, Yael Rosenberg-Hasson, Eric Zhao, Robert Schutt, Roberto Bolli, Jay H. Traverse, Carl J. Pepine, Timothy D. Henry, Ivonne H. Schulman, Lem Moyé, Doris A. Taylor, Phillip C. Yang

Medicine - Cardiology Division

Research output: Contribution to journal › Article › peer-review

19 Scopus citations

Abstract

Bone marrow mononuclear cell (BM-MNC) therapy in ST-elevation acute myocardial infarction (STEMI) has no biological inclusion criteria. Here, we analyzed 63 biomarkers and cytokines in baseline plasma samples from 77 STEMI patients treated with BM-MNCs in the TIME and Late-TIME trials as well as 61 STEMI patients treated with placebo. Response to cell therapy was defined by changes in left ventricular ejection fraction, systolic/diastolic volumes, and wall motion indexes. We investigated the clinical value of circulating proteins in outcome prediction using significance testing, partial least squares discriminant analysis, and receiver operating characteristic (ROC) analysis. Responders had higher biomarker levels (76-94% elevated) than non-responders. Several biomarkers had values that differed significantly (P < 0.05) between responders and non-responders including stem cell factor, platelet-derived growth factor, and interleukin-15. We then used these lead candidates for ROC analysis and found multiple biomarkers with values areas under the curve >0.70 including interleukin 15. These biomarkers were not involved in the placebo-treated subjects suggesting that they may have predictive power. We conclude that plasma profiling after STEMI may help identify patients with a greater likelihood of response to cell-based treatment. Prospective trials are needed to assess the predictive value of the circulating biomarkers.

Original language	English (US)
Article number	4419
Journal	Scientific reports
Volume	7
Issue number	1
DOIs	https://doi.org/10.1038/s41598-017-04801-7
State	Published - Dec 1 2017

Bibliographical note

Publisher Copyright:
© 2017 The Author(s).

Access

10.1038/s41598-017-04801-7

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5493650

OpenUrl availability

Full text

Cite this

Jokerst, J. V., Cauwenberghs, N., Kuznetsova, T., Haddad, F., Sweeney, T., Hou, J., Rosenberg-Hasson, Y., Zhao, E., Schutt, R., Bolli, R., Traverse, J. H., Pepine, C. J., Henry, T. D., Schulman, I. H., Moyé, L., Taylor, D. A., & Yang, P. C. (2017). Circulating Biomarkers to Identify Responders in Cardiac Cell therapy. Scientific reports, 7(1), Article 4419. https://doi.org/10.1038/s41598-017-04801-7

Jokerst, JV, Cauwenberghs, N, Kuznetsova, T, Haddad, F, Sweeney, T, Hou, J, Rosenberg-Hasson, Y, Zhao, E, Schutt, R, Bolli, R, Traverse, JH, Pepine, CJ, Henry, TD, Schulman, IH, Moyé, L, Taylor, DA & Yang, PC 2017, 'Circulating Biomarkers to Identify Responders in Cardiac Cell therapy', Scientific reports, vol. 7, no. 1, 4419. https://doi.org/10.1038/s41598-017-04801-7

@article{7d15459fc4fe4caea12c0f443425ae8a,

title = "Circulating Biomarkers to Identify Responders in Cardiac Cell therapy",

abstract = "Bone marrow mononuclear cell (BM-MNC) therapy in ST-elevation acute myocardial infarction (STEMI) has no biological inclusion criteria. Here, we analyzed 63 biomarkers and cytokines in baseline plasma samples from 77 STEMI patients treated with BM-MNCs in the TIME and Late-TIME trials as well as 61 STEMI patients treated with placebo. Response to cell therapy was defined by changes in left ventricular ejection fraction, systolic/diastolic volumes, and wall motion indexes. We investigated the clinical value of circulating proteins in outcome prediction using significance testing, partial least squares discriminant analysis, and receiver operating characteristic (ROC) analysis. Responders had higher biomarker levels (76-94% elevated) than non-responders. Several biomarkers had values that differed significantly (P < 0.05) between responders and non-responders including stem cell factor, platelet-derived growth factor, and interleukin-15. We then used these lead candidates for ROC analysis and found multiple biomarkers with values areas under the curve >0.70 including interleukin 15. These biomarkers were not involved in the placebo-treated subjects suggesting that they may have predictive power. We conclude that plasma profiling after STEMI may help identify patients with a greater likelihood of response to cell-based treatment. Prospective trials are needed to assess the predictive value of the circulating biomarkers.",

author = "Jokerst, {Jesse V.} and Nicholas Cauwenberghs and Tatiana Kuznetsova and Francois Haddad and Timothy Sweeney and Jiayi Hou and Yael Rosenberg-Hasson and Eric Zhao and Robert Schutt and Roberto Bolli and Traverse, {Jay H.} and Pepine, {Carl J.} and Henry, {Timothy D.} and Schulman, {Ivonne H.} and Lem Moy{\'e} and Taylor, {Doris A.} and Yang, {Phillip C.}",

note = "Publisher Copyright: {\textcopyright} 2017 The Author(s).",

year = "2017",

month = dec,

day = "1",

doi = "10.1038/s41598-017-04801-7",

language = "English (US)",

volume = "7",

journal = "Scientific reports",

issn = "2045-2322",

publisher = "Nature Publishing Group",

number = "1",

}

TY - JOUR

T1 - Circulating Biomarkers to Identify Responders in Cardiac Cell therapy

AU - Jokerst, Jesse V.

AU - Cauwenberghs, Nicholas

AU - Kuznetsova, Tatiana

AU - Haddad, Francois

AU - Sweeney, Timothy

AU - Hou, Jiayi

AU - Rosenberg-Hasson, Yael

AU - Zhao, Eric

AU - Schutt, Robert

AU - Bolli, Roberto

AU - Traverse, Jay H.

AU - Pepine, Carl J.

AU - Henry, Timothy D.

AU - Schulman, Ivonne H.

AU - Moyé, Lem

AU - Taylor, Doris A.

AU - Yang, Phillip C.

PY - 2017/12/1

Y1 - 2017/12/1

N2 - Bone marrow mononuclear cell (BM-MNC) therapy in ST-elevation acute myocardial infarction (STEMI) has no biological inclusion criteria. Here, we analyzed 63 biomarkers and cytokines in baseline plasma samples from 77 STEMI patients treated with BM-MNCs in the TIME and Late-TIME trials as well as 61 STEMI patients treated with placebo. Response to cell therapy was defined by changes in left ventricular ejection fraction, systolic/diastolic volumes, and wall motion indexes. We investigated the clinical value of circulating proteins in outcome prediction using significance testing, partial least squares discriminant analysis, and receiver operating characteristic (ROC) analysis. Responders had higher biomarker levels (76-94% elevated) than non-responders. Several biomarkers had values that differed significantly (P < 0.05) between responders and non-responders including stem cell factor, platelet-derived growth factor, and interleukin-15. We then used these lead candidates for ROC analysis and found multiple biomarkers with values areas under the curve >0.70 including interleukin 15. These biomarkers were not involved in the placebo-treated subjects suggesting that they may have predictive power. We conclude that plasma profiling after STEMI may help identify patients with a greater likelihood of response to cell-based treatment. Prospective trials are needed to assess the predictive value of the circulating biomarkers.

AB - Bone marrow mononuclear cell (BM-MNC) therapy in ST-elevation acute myocardial infarction (STEMI) has no biological inclusion criteria. Here, we analyzed 63 biomarkers and cytokines in baseline plasma samples from 77 STEMI patients treated with BM-MNCs in the TIME and Late-TIME trials as well as 61 STEMI patients treated with placebo. Response to cell therapy was defined by changes in left ventricular ejection fraction, systolic/diastolic volumes, and wall motion indexes. We investigated the clinical value of circulating proteins in outcome prediction using significance testing, partial least squares discriminant analysis, and receiver operating characteristic (ROC) analysis. Responders had higher biomarker levels (76-94% elevated) than non-responders. Several biomarkers had values that differed significantly (P < 0.05) between responders and non-responders including stem cell factor, platelet-derived growth factor, and interleukin-15. We then used these lead candidates for ROC analysis and found multiple biomarkers with values areas under the curve >0.70 including interleukin 15. These biomarkers were not involved in the placebo-treated subjects suggesting that they may have predictive power. We conclude that plasma profiling after STEMI may help identify patients with a greater likelihood of response to cell-based treatment. Prospective trials are needed to assess the predictive value of the circulating biomarkers.

UR - http://www.scopus.com/inward/record.url?scp=85021656796&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85021656796&partnerID=8YFLogxK

U2 - 10.1038/s41598-017-04801-7

DO - 10.1038/s41598-017-04801-7

M3 - Article

C2 - 28667255

AN - SCOPUS:85021656796

SN - 2045-2322

VL - 7

JO - Scientific reports

JF - Scientific reports

IS - 1

M1 - 4419

ER -

Circulating Biomarkers to Identify Responders in Cardiac Cell therapy

Abstract

Bibliographical note

Access

OpenUrl availability

Other files and links

Fingerprint

Cite this